Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Takeda
- 29 Sep 2016 Primary endpoint has been met. (Change from Baseline to Week 6 in Trough Clinic Sitting Systolic Blood Pressure (SBP))
- 29 Sep 2016 Results presented at the 26th Scientific Meeting of the International Society of Hypertension
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.